Chimeric Therapeutics Limited

CHMMFOTCHealthcare

$0.000.00(0.00%)

$0.0052-Week Range$0.00

Mkt Cap$4M

P/E—

EPS—

Div Yield—

Volume30K

Monitoring…

Chimeric Therapeutics Limited (CHMMF) Overview

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Limited operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for CHMMF.

Healthcare Earnings History Insider Trading

Pulse Score

D+49.5/100

Value

13/20

Growth

7.5/20

Health

8/20

Momentum

10.5/20

Sentiment

10.5/20

AI Quick Take

AI analysis is being generated. Visit the AI Intel tab for detailed analysis.

Price Trend (30D)

52W Low: $0.0052W High: $0.00

Analyst Consensus

No analyst coverage available.

Earnings Track Record

Aug 26

Miss +0.0%

Aug 26

Miss +0.0%

Feb 26

Miss +0.0%

Feb 25

Miss +0.0%

Latest Signals

How Much Would You Have if You Had Invested $2,000...

17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

18h ago

Key Statistics

Market Cap

$4.4M

P/E Ratio

-0.2

EPS

$-0.00

Volume

30K

Avg Volume

—

Open

$0.00

Prev. Close

$0.00

Day Range

$0.00 - $0.00

50-Day Avg

$0.00

200-Day Avg

$0.00

52W High

$0.00

52W Low

$0.00

$0.0052-Week Range$0.00

Price Performance

0.0%

YTD

0.0%

-98.6%

-98.5%

Growth Rates (YoY)

Revenue

0.0%

Net Income

16.8%

EPS

57.2%

Free Cash Flow

3.5%

FY 2025 vs FY 2024

Shares & Float

Outstanding

4.42B

Float

2.57B

Free Float

58.3%

Earnings Track Record

✓

Feb 23

+63.8%

✓

Jun 23

+15.5%

✓

Apr 24

+123.0%

✓

Aug 24

+23.0%

—

Feb 25

—

Feb 26

—

Aug 26

—

Aug 26

Beat estimates 4 of 4 quarters (100%)

About

CEO

Rebecca McQualter

Sector

Healthcare

Industry

Biotechnology

Website

chimerictherapeutics.com

Latest Chimeric Therapeutics Limited News

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

The Motley Fool·17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

Schwab Network·18h ago

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Motley Fool·21h ago

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

The Motley Fool·21h ago

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

CNBC·23h ago

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Defense World·1d ago

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Defense World·1d ago

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL

Defense World·1d ago

Financial Summary

ExchangeOther OTC

ISINAU0000121576

Market Cap$4.4M

Beta0.854

Phone61 3 9824 5254

Address62 Lygon Street, Carlton

CountryAU

IPO Date2022-11-30

AI Summary Hub

StoxPulse AI results for CHMMF: Pulse Score 49.5/100. Primary sentiment trends from 15 news sources and 0 SEC filings indicate a neutral outlook.

Chimeric Therapeutics Limited